Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J9042
    Short Description Brentuximab vedotin inj
    Long Description Injection, brentuximab vedotin, 1 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1D
    Action code N
    Type of service 1
    Effective date 2013-01-01
    Date Added 2013-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    51144005001 J9042 Brentuximab vedotin inj Adcetris SEATTLE GENETICS 1mg 1 1 50 50
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 1mg
    HCPCS/CPT Billing Units 1
    Total doses ordered
    Billing Units 1

    Drug Details

    • Brentuximab vedotin injection is used alone or in combination with other chemotherapy medications to treat adult patients with certain types of Hodgkin lymphoma. It is also used alone or in combination with other chemotherapy to treat certain types of anaplastic large cell lymphoma (sALCL), other certain types of peripheral T-cell lymphomas (PTCL; a type of non-Hodgkin lymphoma) and primary cutaneous anaplastic large cell lymphoma (pcALCL; a type of non-Hodgkin's lymphoma) in adult patients. Brentuximab vedotin is used in combination with other chemotherapy in pediatric patients 2 years or older as first treatment for Hodgkin lymphoma. Brentuximab vedotin injection is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.